ArticleQuantitative imaging in medicine and surgery2025
Role of dynamic contrast-enhanced and dynamic susceptibility contrast imaging in evaluating the biological features of glioma.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating tumor cells as a recurrence risk marker in glioma: a retrospective study.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the limitations of conventional imaging in accurately grading gliomas, predicting molecular subtypes, and assessing tumor proliferation and angiogenesis, there is a growing need for advanced quantitative magnetic resonance imaging (MRI) biomarkers. This study aimed to compare the diagnostic performance of histogram features of dynamic contrast enhanced (DCE) and dynamic susceptibility contrast (DSC) imaging in predicting glioma grade and genotyping, as well as to explore the association between DCE and DSC with Ki-67 and microvascular density (MVD). Methods: Forty-six patients with gliomas were enrolled prospectively. The histogram features of DCE and DSC were extracted from the entire tumor and compared among subgroups based on the grades and status of isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion. Pearson correlation analyses were employed to examine the associations among Ki-67, MVD, and histogram features of perfusion model. Receiver operating characteristic (ROC) analyses were used to evaluate the accuracy of DCE and DSC in differentiating glioma grades and genotypes, while Cox regression analyses identified prognostic factors associated with survival after surgical resection. Results: A cohort of 46 patients with IDH-mutant (n=23) and IDH-wildtype (n=23) gliomas was analyzed. DCE-MRI histogram features demonstrated superior performance to DSC parameters in both IDH genotyping and tumor grading. For IDH discrimination, 90th percentile of volume fraction of the extravascular-extracellular space (Ve) [area under the curve (AUC) =0.849, sensitivity 91.3%, specificity 78.3%] and mean value of volume transfer constant (Ktrans) (AUC =0.847, sensitivity 87.0%, specificity 82.6%) showed optimal performance (both P<0.001). In contrast, DSC-derived relative cerebral blood volume (rCBV) (AUC =0.577) and relative cerebral blood flow (rCBF) (AUC =0.537) exhibited limited diagnostic value (P>0.05). In tumor grading, 90th percentile of Ve (AUC =0.923) and mean value of Ktrans (AUC =0.908) achieved near-perfect differentiation (sensitivity 83.9%, specificity 93.3%; P<0.001). While DSC-derived parameters showed improved performance compared to genotyping (rCBV: AUC =0.742, P=0.008; rCBF: AUC =0.688, P=0.040), DCE-based models remained significantly superior (DeLong's test P<0.05 for all comparisons). Significant correlations were observed between DCE parameters and both Ki-67 proliferation index (r=0.42-0.51) and MVD (r=0.35-0.56; all P<0.05). Survival analysis identified three independent prognostic factors: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [hazard ratio (HR) =4.15, 95% confidence interval (CI): 1.10-15.68, P=0.04], elevated Ktrans (HR =1.08, 95% CI: 1.01-1.17, P=0.03), and rCBV (HR =1.87, 95% CI: 1.17-2.97, P=0.009). Conclusions: The histogram features of DCE and DSC demonstrate exceptional diagnostic efficacy in glioma grading, with DCE providing deeper insights into the molecular characteristics of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.